Table 3. Grade 3–4 adverse events.

	FOLFOX4 (N=52)	5FU-cisplatin (N=43)
	n (%)	n (%)
Number of patients with any grade 3 or 4 adverse events	39 (75.0)	31 (72.1)
Haematological	39 (75.0)	31 (72.1)
Neutropenia	12 (23.1)	9 (20.9)
Thrombocytopenia	5 (9.6)	5 (11.6)
Febrile neutropenia	5 (9.6)	2 (4.7)
Anaemia	2 (3.8)	3 (7.0)
Leucopenia	3 (5.8)	1 (2.3)
Febrile bone marrow aplasia	1 (1.9)	1 (2.3)
Pancytopenia	1 (1.9)	1 (2.3)
Dysphagia	10 (19.2)	7 (16.3)
Radiation-related oesophagitis	4 (5.8)	6 (14.0)
Stomatitis	3 (5.8)	0
Odynophagia	1 (1.9)	2 (4.7)
Oesophageal pain	1 (1.9)	1 (2.3)
Asthenia	4 (7.7)	4 (9.3)
Mucosal inflammation	4 (7.7)	1 (2.3)
Fatigue	2 (3.8)	2 (4.7)
Chest pain	0	2 (4.7)
Neutropenic infection	2 (3.8)	2 (4.7)
Weight decreased	2 (3.8)	2 (4.7)
Anorexia	2 (3.8)	2 (4.7)
Hypocalcaemia	0	2 (4.7)